{
    "title": "114_hr639",
    "content": "The \"Improving Regulatory Transparency for New Medical Therapies Act\" establishes scheduling of substances included in new FDA-approved drugs, specifying the effective date of drug approval under the Federal Food, Drug, and Cosmetic Act. The approval of an application for a drug under the Controlled Substances Act is delayed until an interim final rule controlling the drug is issued. The approval of a drug application under the Controlled Substances Act is delayed until an interim final rule controlling the drug is issued. The effective date of approval for biological products is determined by the later of the approval date of the application or the issuance date of the interim final rule. The approval of a drug application under the Controlled Substances Act is delayed until an interim final rule controlling the drug is issued. For biological products, the effective date of approval is determined by the later of the approval date of the application or the issuance date of the interim final rule. Approval of a biological product application under the Controlled Substances Act is delayed until an interim final rule is issued. The effective date of approval is determined by the later of the approval date of the application or the issuance date of the interim final rule. The effective date of approval for a biological product application is determined by the later of the approval date of the application or the issuance date of the interim final rule. The effective date of approval for animal drugs under the Controlled Substances Act is determined by the date the Secretary issues a scientific and medical evaluation and recommends controls. The approval of a drug application under subsection (b) will be delayed until an interim final rule controlling the drug is issued under the Controlled Substances Act. The \"date of approval\" is defined as the later of the date the application is approved under subsection (c) or the date of issuance of the interim final rule. The term \"date of approval\" for a drug application is defined as the later of the approval under subsection (c) or the issuance of the interim final rule controlling the drug. Additionally, conditional approval may be granted for certain drug applications under subsection (a). The Food, Drug, and Cosmetic Act is amended to include provisions for conditional approval of drug applications pending issuance of interim final rules under the Controlled Substances Act. The Food, Drug, and Cosmetic Act is amended to include provisions for conditional approval of drug applications pending issuance of interim final rules under the Controlled Substances Act. The date of approval for an application is defined as the later of the conditional approval date or the issuance date of the interim final rule controlling the drug. Indexing of legally marketed unapproved new animal drugs is also addressed in the Act. The Food, Drug, and Cosmetic Act now allows for conditional approval of drug applications until the issuance of interim final rules under the Controlled Substances Act. The approval date is determined by the later of the conditional approval date or the issuance date of the interim final rule controlling the drug. Additionally, indexing of legally marketed unapproved new animal drugs is addressed in the Act. The Food, Drug, and Cosmetic Act allows for conditional approval of drug applications until the issuance of interim final rules under the Controlled Substances Act. The approval date for designated new animal drugs is determined by the later of the conditional approval date or the issuance date of the interim final rule controlling the drug. The Controlled Substances Act allows for conditional approval of drug applications until the issuance of interim final rules. The approval date for designated new animal drugs is determined by the later of the conditional approval date or the issuance date of the interim final rule controlling the drug. The Controlled Substances Act allows for conditional approval of drug applications until the issuance of interim final rules. The Secretary of Health and Human Services may recommend scheduling newly approved drugs under specific controlled substance schedules. The Secretary of Health and Human Services may recommend controlling newly approved drugs under specific schedules, and the Attorney General must issue an interim final rule within 90 days using specified procedures. The Attorney General must issue an interim final rule within 90 days based on recommendations from the Secretary of Health and Human Services regarding drug scheduling. The date for this rule is determined by receiving the necessary evaluations and approvals from the Secretary. The Attorney General must issue an interim final rule within 90 days based on recommendations from the Secretary of Health and Human Services regarding drug scheduling. The rule becomes immediately effective without needing to demonstrate good cause, allowing for public comment and hearing requests. The interim final rule issued by the Attorney General becomes effective immediately without the need to demonstrate good cause. Interested persons can comment and request a hearing. After the proceedings, a final rule will be issued based on scheduling criteria. Section 156 of title 35, United States Code, is amended to extend the patent term for drug products under certain conditions defined by the Secretary of Health and Human Services. The amendment to Section 156 of title 35, United States Code, extends the patent term for drug products under specified conditions set by the Secretary of Health and Human Services. Additionally, if the Secretary intends to recommend controls under the Controlled Substances Act for a drug product, it will be considered approved or indexed under relevant provisions of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act, with permission for commercial marketing or use. The term 'covered date' refers to the later of the approval date under specific provisions of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act, or the conditional approval date under the Federal Food, Drug, and Cosmetic Act. SEC. 3. ENHANCING NEW DRUG DEVELOPMENT. Section 303 of the Controlled Substances Act (21 U.S.C. 823) is amended to include provisions for enhancing new drug development. The Controlled Substances Act is amended to enhance new drug development by expediting registration for manufacturing controlled substances for clinical trials. The Attorney General must register the applicant within 180 days of application acceptance. The Controlled Substances Act requires the Attorney General to register the applicant within 180 days of application acceptance for manufacturing controlled substances for clinical trials. Additionally, for registration for use in clinical trials, a notice of application must be issued within 90 days of acceptance, with registration or a show cause order to follow within 90 days after the comment period ends. The Attorney General must register the applicant within 180 days of application acceptance for manufacturing controlled substances for clinical trials. A notice of application must be issued within 90 days of acceptance, with registration or a show cause order to follow within 90 days after the comment period ends. Additionally, re-exportation among members of the European Economic Area is addressed in the Controlled Substances Import and Export Act. The Controlled Substances Import and Export Act is amended to allow re-exportation among members of the European Economic Area. The Controlled Substances Import and Export Act is amended to allow re-exportation of controlled substances among members of the European Economic Area. The Controlled Substances Import and Export Act is amended to allow re-exportation of controlled substances among members of the European Economic Area, subject to specific conditions for each country involved. The Controlled Substances Import and Export Act is amended to allow re-exportation among members of the European Economic Area, with specific conditions for documentation within 30 days of each re-exportation. The Controlled Substances Import and Export Act is amended to allow re-exportation within the European Economic Area, with requirements for documentation within 30 days of each re-exportation. The Attorney General cannot impede re-exportation of controlled substances among European Economic Area countries, including by enforcing time restrictions or requiring specific consignee information. The Attorney General cannot restrict re-exportation of controlled substances among European Economic Area countries, including by enforcing time restrictions or requiring specific consignee information. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}